Overview
| MDL | MFCD25976660 |
|---|
| Molecular Weight | 473.57 |
|---|
| Molecular Formula | C30H27N5O |
|---|
| SMILES | O=C(NC1=CC(CNC)=CC=C1C)C2=CC=C(NC3=NC(C4=CC=CC=C4)=C5C=CC=CC5=N3)C=C2 |
|---|
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg |
| 1 mM | 2.1116 mL | 10.5581 mL | 21.1162 mL |
| 5 mM | 0.4223 mL | 2.1116 mL | 4.2232 mL |
| 10 mM | 0.2112 mL | 1.0558 mL | 2.1116 mL |
| 50 mM | 0.0422 mL | 0.2112 mL | 0.4223 mL |
Description
BMS-833923 (XL139) is an orally bioavailable antagonist. Phase 2.
In vitro
BMS-833923 reduces hedgehog pathway activity, decreases cell proliferation and induces apoptosis via the intrinsic pathway in esophageal adenocarcinoma (EAC) cell lines. BMS-833923 dose-dependently affects canonical and prostate hedgehog signature gene transcription in vitro.
